About replimune group inc - REPL
Replimune Group, Inc. is a clinical-stage biotechnology company. It engages in the business of developing oncolytic immunotherapies for the treatment of cancer. The company was founded by Philip Astley-Sparke, Colin A. Love, and Robert Coffin in March 2015 and is headquartered in Woburn, MA.
REPL At a Glance
Replimune Group, Inc.
500 Unicorn Park Drive
Woburn, Massachusetts 01801
| Phone | 1-781-222-9600 | Revenue | 0.00 | |
| Industry | Biotechnology | Net Income | -313,940,000.00 | |
| Sector | Health Technology | Employees | 465 | |
| Fiscal Year-end | 03 / 2027 | |||
| View SEC Filings |
REPL Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | N/A |
| Price to Book Ratio | 3.808 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | -1.754 |
| Enterprise Value to Sales | N/A |
| Total Debt to Enterprise Value | 0.202 |
REPL Efficiency
| Revenue/Employee | N/A |
| Income Per Employee | -675,139.785 |
| Receivables Turnover | N/A |
| Total Asset Turnover | N/A |
REPL Liquidity
| Current Ratio | 4.794 |
| Quick Ratio | 4.794 |
| Cash Ratio | 4.618 |
REPL Profitability
| Gross Margin | N/A |
| Operating Margin | N/A |
| Pretax Margin | N/A |
| Net Margin | N/A |
| Return on Assets | -71.05 |
| Return on Equity | -107.883 |
| Return on Total Capital | -113.031 |
| Return on Invested Capital | -82.428 |
REPL Capital Structure
| Total Debt to Total Equity | 67.156 |
| Total Debt to Total Capital | 40.176 |
| Total Debt to Total Assets | 33.571 |
| Long-Term Debt to Equity | 64.724 |
| Long-Term Debt to Total Capital | 38.721 |